Schizophrenia Clinical Trials

256 recruiting

Schizophrenia Trials at a Glance

290 actively recruiting trials for schizophrenia are listed on ClinicalTrialsFinder across 6 cities in 44 countries. The largest study group is Not Applicable with 153 trials, with the heaviest enrollment activity in Atlanta, Chicago, and Boston. Lead sponsors running schizophrenia studies include Shanghai Mental Health Center, China Medical University Hospital, and Centre for Addiction and Mental Health.

Browse schizophrenia trials by phase

Treatments under study

Understanding Schizophrenia Clinical Trials

Every antipsychotic medication used to treat schizophrenia today, from first-generation drugs like chlorpromazine to newer options like cariprazine (Vraylar) and lumateperone (Caplyta), was developed through clinical trials. In 2024, the FDA approved cobenfy (xanomeline-trospium), the first truly novel mechanism for schizophrenia treatment in decades, targeting muscarinic receptors rather than dopamine, a breakthrough that only became possible through years of clinical trial research. For the approximately 2.8 million adults in the United States living with schizophrenia, ongoing trials are exploring treatments that aim to address not just psychotic symptoms but also the cognitive and social difficulties that current medications often leave untreated.

Why Consider a Clinical Trial?

Current antipsychotic medications primarily target the positive symptoms of schizophrenia, such as hallucinations and delusions, but many people continue to struggle with negative symptoms like social withdrawal, flat affect, and lack of motivation, as well as cognitive difficulties affecting memory, attention, and decision-making. These unaddressed symptoms are often the biggest barriers to living independently and maintaining employment. Clinical trials are testing treatments specifically designed to target these gaps, including cognitive enhancers, glutamate-modulating drugs, and novel anti-inflammatory approaches. Many people with schizophrenia also experience significant side effects from current medications, including weight gain, metabolic syndrome, and movement disorders. Newer agents being studied in clinical trials aim to provide symptom control with a more favorable side effect profile. Participating in a trial also means receiving care from a specialized research team with deep expertise in schizophrenia, often at major academic medical centers, with consistent and thorough monitoring throughout the study period.

Frequently Asked Questions

Common questions about Schizophrenia clinical trials

Yes, many trials allow participants to continue their current medication. Some studies test add-on treatments that supplement your existing antipsychotic, while others may require a supervised medication change. The research team will explain exactly what is required and will not make any changes without your consent.

Yes, cognitive impairment is a major focus of current schizophrenia research. Trials are testing pro-cognitive medications, computerized cognitive training programs, and combination approaches. These studies typically measure improvements in memory, attention, and problem-solving using standardized neuropsychological tests.

All schizophrenia trials have safety protocols for symptom worsening. If your symptoms significantly worsen, the research team can provide rescue medication, adjust your treatment, or withdraw you from the study with a safe transition plan back to standard care. Your wellbeing always takes priority over the research protocol.

Most schizophrenia trials welcome caregiver involvement. Family members can attend study visits, help with transportation, and assist with medication adherence. Some studies specifically include caregiver assessments as part of the outcome measures. The research team will work with you and your support network.

Most schizophrenia trials are conducted on an outpatient basis, meaning you attend scheduled visits at the research site but live at home. Some acute-phase trials may begin with a brief inpatient stabilization period. The study design will be clearly explained before you consent to participate.

Showing 120 of 290 trials

Recruiting
Phase 2

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

Schizophrenia
Novartis Pharmaceuticals142 enrolled7 locationsNCT07467993
Recruiting

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

Schizophrenia
Bristol-Myers Squibb1,500 enrolled45 locationsNCT07379827
Recruiting
Phase 4

A Study to Evaluate the Effect of KarXT on Urological Safety

Schizophrenia
Bristol-Myers Squibb60 enrolled14 locationsNCT07221877
Recruiting

Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

Schizophrenia
Bristol-Myers Squibb300 enrolled18 locationsNCT07101094
Recruiting
Not Applicable

Multimodal Physical Exercise Program (Physical Exercise for Psychosis) for People With Psychosis Treated With Long-Acting Injectable Antipsychotics

Psychotic DisordersSevere Mental IllnessSchizophrenia Spectrum Disorders (SSD)
University of Trás-os-Montes and Alto Douro44 enrolled1 locationNCT07360665
Recruiting
Phase 1

Evaluating Safety, Tolerability and Pharmacokinetic of Multiple Ascending Doses of VV119

Schizophrenia
Vigonvita Life Sciences40 enrolled4 locationsNCT06504290
Recruiting
Phase 1Phase 2

Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine

SchizophreniaMajor Depressive DisorderBipolar I Disorder
Mapi Pharma Ltd.24 enrolled6 locationsNCT07185815
Recruiting
Phase 2

Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia

Schizophrenia
University of California, Los Angeles40 enrolled1 locationNCT05778591
Recruiting

Biomarker Research on Ultra-High-Field MRI Combined With Visual Perception Assessment in the Diagnosis and Treatment Outcomes of Severe Mental Disorders

SchizophreniaMajor Depressive Disorder (MDD)Bipolar Disorder+1 more
Second Affiliated Hospital, School of Medicine, Zhejiang University320 enrolled1 locationNCT07479758
Recruiting
Not Applicable

Multi-target TMS for Schizophrenia Negative Symptoms

SCHIZOPHRENIA 1 (Disorder)
Shanghai Mental Health Center64 enrolled1 locationNCT07559084
Recruiting

Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Healthy ControlSchizophreniaPost Traumatic Stress Disorder+4 more
Yale University100 enrolled1 locationNCT01730781
Recruiting
Not Applicable

The Effect of Game-Based Intervention on the Cognition of Schizophrenia Patients

Schizophrenia
Shanghai Mental Health Center84 enrolled1 locationNCT07557381
Recruiting
Not Applicable

Effects of Gamified Rehabilitation on Cognitive and Psychosocial Outcomes in Inpatients With Schizophrenia

Schizophrenia
Shanghai Mental Health Center84 enrolled1 locationNCT07557368
Recruiting
Not Applicable

The Key to Integrated Trauma Treatment in Psychosis Trial

Schizophrenia DisordersPsychiatric DiagnosisPsychological Trauma, Historical
Haukeland University Hospital187 enrolled11 locationsNCT06608706
Recruiting

Database Registry for Neural Network Biomarkers in Psychosis

SchizophreniaSchizoaffective Disorder
University of Texas Southwestern Medical Center1,000 enrolled1 locationNCT01409109
Recruiting
Phase 3

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.522 enrolled73 locationsNCT06894212
Recruiting
Phase 2

A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

Schizophrenia
MapLight Therapeutics500 enrolled5 locationsNCT07459647
Recruiting
Phase 2

A Study of Brenipatide in Adult Participants With Schizophrenia

Schizophrenia
Eli Lilly and Company450 enrolled102 locationsNCT07410507
Recruiting
Phase 4

A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

SchizophreniaMajor Depressive DisorderBipolar Disorder+2 more
Neurocrine Biosciences50 enrolled19 locationsNCT07105111
Recruiting
Not Applicable

Examining the Efficacy of a Virtual Reality Cognitive Remediation Program for People Living With Psychosis

SchizophreniaPsychotic DisordersSchizo Affective Disorder
The Royal Ottawa Mental Health Centre52 enrolled1 locationNCT05973110